| INTRODUCTION
has increased due to advancements in the technology and availability of MRI, and in the scientific evidence supporting its use for MS.
Over the past few years, an increasing number of diseasemodifying treatments (DMTs) have become available that affects the MS disease in several meaningful ways. It has been shown that current
DMTs can reduce focal inflammatory activity as well as the accumulation of disability 6 and the rate of brain atrophy. 7 The currently available DMTs differ in respect to treatment efficacy and associated risks, stressing the importance of clinical tools to individualize the choice of DMT and closely monitor the treatment efficacy. 6 Examination with MRI exhibiting a higher sensitivity for inflammatory disease activity than clinical relapses alone, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] is routinely used in this regard and is an important addition to the care of individuals with MS.
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Despite the routine use of MRI in the care of patients with suspected or confirmed MS, there is a lack of scientific evidence defining its optimal use. 21 The MRI protocols, timing, and frequency of investigations, as well as the positioning of patients in the MRI scanner, will in many cases differ between MS care centers. This may influence the reliability of clinical MRI data 22 and thus the diagnostic accuracy as well as the ability to evaluate ongoing DMT.
There is also no complete international expert consensus available for these topics, although they are partially covered in the recent
European consensus guidelines by MAGNIMS (Magnetic Resonance
Imaging in MS). 21, 23 Neurologists and neuroradiologists working in the field of MS in Sweden present a consensus agreement here regarding the use of MRI in MS. The aim was to establish consensus-based recommendations for the use of MRI in the diagnosis and disease monitoring of MS in Sweden. 
| METHODS

| RESULTS
| Clinical indications for MRI scans
There are a number of situations in which MRI investigation provides clinical benefit in the care of an individual with suspected or confirmed MS. The most prominent reasons are diagnostic examination, monitoring of treatment efficacy, and screening for progressive multifocal leukoencephalopathy (PML). The most important clinical situations in which MRI should be performed are summarized in Table 1 .
| Which parts of the CNS should be examined?
Multiple sclerosis disease activity can occur in any part of the CNS. 
| Recommended MRI protocols for diagnosis and follow-up
Recommended MRI brain imaging protocols for diagnostic evaluation and follow-up of confirmed MS cases are specified in Table 2 .
These should be regarded as minimal protocols to provide adequate radiological information in most cases. The protocols can locally be extended with additional sequences, but the recommendations are intended as a minimum common denominator across Swedish hospitals.
In situations where consideration of specific differential diagnoses is warranted, the protocols should be tailored to answer the relevant radiological questions at hand. The diagnostic protocol is more extensive, which allows for the consideration of radiological differential diagnoses required for diagnosing MS. The follow-up protocol is less extensive because its main purpose is to assess the occurrence of new inflammatory disease activity. 
T A B L E 1 Specific clinical situations when MRI investigation is warranted
Situation Reason for MRI examination Aim
Investigation of clinically suspected MS
To find radiological signs that increase/decrease the probability of MS. To assess the level of disease activity here are based on clinical experience and extrapolation of study data on the level of disease activity seen in treated and untreated patients with MS in phase III studies.
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As mentioned above, the degree of disease activity and fre- 
| In what situations should an increased frequency of MRI examinations be considered?
A change in treatment strategy may increase the risk of recurring disease activity. A special situation occurs when switching from treatment with natalizumab to another DMT in a patient seropositive for JC virus.
Early signs of PML can be difficult to detect 36 and onset can occur even after natalizumab discontinuation. 37 A baseline MRI should be 
| In what situations can the frequency of MRI examinations be decreased?
Focal inflammatory activity in MS tends to decrease with age. 40 A decrease in focal inflammatory activity, for this or other reasons, lessens the need for the frequent MRI monitoring recommended for patients with a more active disease. There is currently no evidence available to firmly establish at which age, disease duration, or clinical situations it is acceptable to decrease the frequency of MRI examinations. However, the consensus discussion identified a few situations when less frequent MRI monitoring can be considered (Table 3) . To a large degree, these recommendations are based on clinical experience. 
| Administration of gadolinium-based contrast agent
Detection of gadolinium-based contrast agent (GBCA) enhancing lesions on T1-weighted images suggests that focal inflammatory activity with disruption of the blood-brain barrier has occurred during the last few months. 41 This is of great importance for demonstrating dissemination in time when MS diagnosis is considered. In the setting of disease
T A B L E 3 Examples of situations when decreased MRI monitoring can be considered
Examples of situations when decreased frequency of MRI monitoring can be considered Examples of situations when stopping the MRI monitoring can be considered
In the setting of MS disease that has been relapse free and radiologically stable during repeated follow-up without change in therapy and with clinical variables suggesting a favorable disease course
In the setting of MS disease in a patient of higher age (>55-60 years old) that has been relapse free and radiologically stable during longer time of repeated follow-up without DMT and with clinical variables suggesting a favorable disease course
In the setting of RIS or CIS that has been relapse free and radiologically stable during a repeated follow-up of 3 to 5 years without DMT
In the setting of RIS or CIS that has been relapse free and radiologically stable during a longer repeated follow-up without DMT MRI, magnetic resonance imaging; MS, multiple sclerosis; RIS, radiologically isolated syndrome; DMT, disease-modifying treatment.
T A B L E 4 Recommended information to be included in the referral and radiological report
Diagnostic MRI Routine follow-up MRI
Referral text
The main goal is to communicate the information that the neuroradiologist and the MRI staff will need to be able to correctly prioritize and plan the MRI examination, as well as to provide a context for the neuroradiologist to use as a base for the report. Important information in the referral includes:
• Clinical symptoms and their evolution over time 
Radiological report
The main goal is to communicate the radiological information that is needed to plan the future care of the patient and to decide whether or not an MS diagnosis should be made. Important information in the report includes:
• Which parts of the CNS that have been examined and whether or not GBCA was administered The main goal is to communicate the radiological information that is needed to plan the future care of the patient. Important information in the report includes:
• Which parts of the CNS that have been examined and whether or not GBCA was administered • A description of all (if any) new or enlarged lesions of demyelinating appearance that have been identified compared to previous examinations, preferably the date of the examination(s) used for comparison should be mentioned • A description of the approximate size, localization, and number of lesions of demyelinating appearance • Whether or not any GBCA enhancing lesions have been detected and if so the number and preferably the location of such lesions should be specified • A statement of whether or not any other relevant change has occurred compared to previous examinations GBCA, gadolinium-based contrast agent; MRI, magnetic resonance imaging; MS, multiple sclerosis; RIS, radiologically isolated syndrome; DMT, diseasemodifying treatment; PML, progressive multifocal leukoencephalopathy.
monitoring of confirmed MS, the temporal information provided by detection of GBCA enhancement is less important. The finding of a GBCA enhancing lesion on T1-weighted images is often accompanied by a corresponding lesion detectable on T2-weighted images. 42 Based on this, we assess the value of GBCA administration as lower in the setting of disease monitoring as compared to the diagnostic MRI. However, it cannot be ruled out that GBCA administration may increase sensitivity for new disease activity even at routine follow-up MRI, 42, 43 especially considering the interobserver variability of identifying new or enlarged T2 lesions.
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While short-term use of GBCA generally appears to be safe in individuals with normal renal function, 31, 44 some issues need to be mentioned. Administration of GBCA is associated with a small risk of anaphylaxis 44 and development of nephrogenic systemic fibrosis (NSF). The latter has been associated especially with linear GBCA and renal dysfunction. 45 To minimize risk of NSF, one of the more chemically stable macrocyclic GBCAs should be used.
Potential long-term risks associated with repeated administration of GBCA have not been sufficiently investigated but increased signal intensity of the dentate nucleus and globus pallidus on T1-weighted cerebral MRI scans has been reported after repeated administrations of both linear and macrocyclic GBCA and also in individuals without any major renal impairment. 46, 47 The origin of this increased T1 signal has not been fully established, but histopathologic quantifications of gadolinium in brain tissues suggest deposition of gadolinium in brain tissue associated with repeated use. 48 There is currently no evidence that such gadolinium deposition is harmful, but our opinion is that a cautionary approach is warranted, as gadolinium is toxic in its non-chelated form. 45 For this reason, we suggest that in patients free from relapses and MRI lesions for at least 5 years, MRI could be performed without administration of GBCA. However, if clinical or radiological signs of new inflammatory activity occur, or the patient's treatment strategy is changed, a new MRI including administration of GBCA should be considered.
| What information should be included in the patient referral for MRI and the report from the neuroradiologist?
The information included in the patient referral for the MRI and the subsequent report written by the neuroradiologist is the cornerstones of the communication between the neurologist and the neuroradiologist. Table 4 includes examples of information that is of particular importance in this communication. Table 5 includes examples of templates that can be used for the radiological report.
| Future perspectives
The MAGNIMS collaboration has recently published suggestions for adjustments 34 to the current McDonald criteria for the diagnosis of MS, last revised in 2010. 5 Some important points in the suggested adjustments are the recommendations to:
• add the optic nerve as another individual area to consider for the criteria of dissemination in space;
• require three periventricular lesions for the dissemination in space to the periventricular space to be fulfilled;
• expand the juxtacortical area to the juxtacortical/cortical area and consider cortical lesions in the fulfillment of the criteria for dissemination in space;
• treat all lesions equally, regardless of if they are symptomatic or not;
• use the same radiological criteria to diagnose RIS as is used for MS;
• use the same radiological criteria for dissemination in space for primary progressive MS as for relapsing remitting MS.
Until further considerations have been made regarding the effect of these suggestions on the sensitivity and specificity of diagnosing MS, our consensus agreement will continue using the McDonald 2010 revision criteria. However, these suggestions warrant mentioning here as a perspective on possible future adjustments of the MS diagnostic criteria.
| CONCLUSIONS
Examination with MRI is established as an important tool in the diag- The Swedish consensus panel could agree upon a minimal set of MRI sequences for diagnostic as well as follow-up examinations. 
